Back to search results

Walking Juntos Study: Physical Activity for Hispanic/Latina Adolescent and Young Adult Cancer Survivors

This study, called "Walking Juntos," is for Hispanic or Latino/Latina adolescents and young adults (ages 15-20) who have survived childhood cancer. It aims to see if a home-based physical activity program, designed with your culture in mind, can help you be more active. After cancer treatment, some survivors experience long-term effects like weight gain, tiredness, and lower fitness. This study will compare a special physical activity program, which includes group discussions and social media support, to just using a Fitbit. Researchers will measure your moderate to vigorous physical activity (MVPA) to see if the program helps. The study is looking for 190 participants and is currently recruiting.

Study design
This is an interventional study that will involve 190 participants. It includes a randomized controlled trial where some participants will receive the physical activity intervention and others will receive a Fitbit only.
What's involved
You would participate in Zoom meetings with peers, set physical activity goals, and view private social media content. You would also participate in one-on-one interviews.
Compensation
Not stated in the trial record.
Follow-up
Your moderate to vigorous physical activity will be measured from the start of the study to 11-12 weeks after you are assigned to a group.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06410209

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

Recruiting
PHASE2Ages 15–20InterventionalPrevention
Children's Oncology Group
~190 participants
Updated 2026-02-27 on ClinicalTrials.gov
What's tested:DiscussionGoal SettingInterviewMedia InterventionMedical Device Usage and EvaluationQuestionnaire Administration

At a glance

Recruiting sites
77 of 77 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Moderate to vigorous physical activity (MVPA)
Measured over Baseline to 11-12 weeks post randomization

Conditions

Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Where it's being run

77 sites across 31 states
Florida11
Texas11
California8
Nevada5
Illinois3
Tennessee3
Arizona2
Georgia2

Study leadership

  • Jason A Mendoza · PRINCIPAL_INVESTIGATOR · Children's Oncology Group

Who to contact

Site Public Contact
480-412-3100
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient must be ≥ 15 years and \< 21 years at the time of enrollment
First diagnosis of malignant neoplasm (International Classification of Diseases for Oncology \[ICD-O\] behavior code of "3") in first and continuous remission at the time of enrollment
Curative cancer treatment must have included chemotherapy (including cellular therapy) and/or radiation (including radioactive iodine). Note: Certain stem cell transplant procedures are excluded. Reminder: Children's Oncology Group (COG) therapeutic trial participation is not required
Completed all chemotherapy and/or radiation therapy in the last 3-36 months. This includes completion of all oral (e.g., tyrosine kinase inhibitors) and/or maintenance chemotherapy
Self-report of \< 420 minutes of moderate-to-vigorous physical activity per week as assessed and documented via the study-specific Physical Activity Worksheet. Note: See the case report forms packet on the COG study web page for the study specific Physical Activity Worksheet
Ambulatory and no known medical contraindications to increasing physical activity
No known significant physical or cognitive impairment that would prevent use of the electronic devices used for the protocol intervention (e.g., Fitbit, smartphone, tablet, or computer)
Able to read and write Spanish or English
Self-identify as Hispanic, Latino/Latina/Latinx

Exclusion

Patients with previous allogeneic hematopoietic stem cell transplant (HSCT) are excluded. Note: Patients with previous autologous HSCT, chimeric antigen receptor T-cell (CAR T-cell) therapy, and other cellular cancer therapies can participate as long as all other eligibility criteria are satisfied
Post-menarchal female patients who are pregnant or planning to become pregnant in the next year are excluded. Note: Pregnancy status can be established by clinical history with patient. Post-menarchal female patients are eligible as long as they agree to use an effective contraceptive method (including abstinence) during study participation
Participants who were enrolled in ALTE2031 (Step by Step) cannot enroll in ALTE2321. Participants who were enrolled in ALTE2321 stage 1 (cultural tailoring) cannot enroll to participate in stage 2 (RCT)
All patients and/or their parents or legal guardians must sign a written informed consent. Note: Informed consent may be obtained electronically/online if allowed by local site policy and institutional review board (IRB)/research ethics board (REB) of record
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

What this trial measures

  • Moderate to vigorous physical activity (MVPA)Baseline to 11-12 weeks post randomization

    MVPA will be measured by active minutes using Fitbit. Will report the mean change from baseline to the 11-12-week post randomization timepoint by trial arm alongside corresponding confidence intervals estimated under a linear mixed effects model.